NSCA-1—a novel N-substituted coumalamide derivative—increases Adriamycin sensitivity in HepG2/adriamycin cells through modulating Akt/GSK-3β signaling and p53-dependant apoptotic pathway

详细信息    查看全文

• 作者：Yanhua Fan^a ; ^b ; Jianyu Liu^c ; Dan Liu^a ; Zhipeng Zhou^a ; ^b ; Ying Bao^c ; Jian Wang^c ; Qingchun Zhao^b ; ^{zhaoqingchun1967@163.com} ; Yongnan Xu^a ; ^c ; ^{ynxu@syphu.edu.cn}
• 关键词：HepG2/ADR ; HepG2 cells with Adriamycin resistance ; DOX ; doxorubicin (also called Adriamycin) ; ADR ; Adriamycin (also called Doxorubicin) ; NSCA-1 ; N-(3-((3 4-dimethoxybenzyl)oxy)phenyl)-2-oxo-2H-pyran-5-carboxamide ; MDR ; multidrug resistance ; p-gp ; P-glycoprotein
• 刊名：Environmental Toxicology and Pharmacology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：49
• 期：Complete
• 页码：1-7
• 全文大小：1337 K
• 卷排序：49

文摘

We report the synthesis and biological evaluation of NSCA-1. NSCA-1 exerts synergistic cytotoxicity with Adriacin in HepG2-ADR cells. NSCA-1 significantly decreased the expression of p-Akt and p-GSK3β. NSCA-1enhanced the sensitivity of HepG2-ADR cells to Adriacin via P-gp inhibition. NSCA-1 enhanced Adriacin induced apoptosis via p53 dependent pathway.